<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525926</url>
  </required_header>
  <id_info>
    <org_study_id>14-APN-02</org_study_id>
    <nct_id>NCT02525926</nct_id>
  </id_info>
  <brief_title>Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension</brief_title>
  <acronym>DENERV'AP</acronym>
  <official_title>Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pulmonary hypertension is a rare condition that leads to right ventricular dysfunction and
      premature death. Only modest improvements of outcomes have been observed with the current
      available advanced specific drug therapy. Pulmonary hypertension advanced therapy is also
      expensive and leads to frequent adverse effects, sometimes serious. Results from a pilot
      study, the first-in-man experience of pulmonary artery denervation, demonstrated a clinical
      improvement in 13 patients with severe pulmonary hypertension despite optimal medical
      management. However this single non-randomized study requires confirmation.

      The investigators propose a prospective multi-center, randomized, single-blinded trial. Its
      main objective will be to assess, in patients with uncontrolled pulmonary hypertension
      despite optimal medical management, the efficacy of pulmonary artery denervation in reducing
      mean pulmonary artery pressure (mPAP) at six months, compared to continued medical treatment
      following a simulated (sham) procedure.

      The principal evaluation criteria will be the mPAP change (in mm Hg) as measured by right
      heart catheterization.

      The study will run for 18 months and it will be necessary to recruit 50 patients.

      All adult patients (with the exception of pregnant women and individuals unable to receive an
      appropriate information and to give their free and informed consent) with uncontrolled
      pulmonary arterial hypertension despite optimal medical management will be invited to
      participate, in the absence of any exclusion criteria.

      The investigators will also measure changes in clinical, biological, echocardiographic and
      hemodynamic prognostic markers in both groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean pulmonary artery pressure (in mmHg) measured during right heart catheterization</measure>
    <time_frame>at 6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean pulmonary artery pressure (in mmHg) from the initial procedure</measure>
    <time_frame>at 3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vascular resistance (in Wood units) measured during right cardiac catheterization.</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters: NYHA class</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters: Borg dyspnea rating scale</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters: 6-minute walk test (distance walked in meters),</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters: oxygen dependence (quantity of oxygen in L/min),</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical parameters: ECG with supra ventricular arrhythmia.</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological parameters: levels of Brain Natriuretic Peptide (pg/ml) in non-fasting morning samples.</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological parameters: levels of troponin Ic (ng/ml) in non-fasting morning samples.</measure>
    <time_frame>at 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic parameters of right ventricular function</measure>
    <time_frame>at 6 month</time_frame>
    <description>Right ventricular diameter at admission (mm) in 4-chamber view
Right ventricular systolic function: tricuspid annular plane systolic excursion (TAPSE) (mm), peak S-wave velocity at the lateral tricuspid ring (cm/s), Right ventricular fractional area change (%), acceleration (m/s2) and peak isovolumic contraction (cm/s), pulmonary systolic time velocity integral (cm), longitudinal deformation of right ventricular free wall using speckle-tracking imaging (%)
Right ventricular adaptation: right ventricular Tei-index and presence of pericardial effusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other hemodynamic parameters obtained by right cardiac catheterization</measure>
    <time_frame>at 6 month</time_frame>
    <description>Cardiac index/output using thermodilution (L/min/m2)
Right atrial pressure (mmHg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>denervation</intervention_name>
    <description>The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.</description>
    <arm_group_label>denervation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sham procedure</intervention_name>
    <description>Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a &quot; sham &quot; procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.
Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study.</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pulmonary artery hypertension (group 1 of the Nice classification of
             pulmonary hypertension)

               -  Aged over 18 years old

               -  NYHA class III or IV

               -  Not controlled by optimal medical management as defined by:

                    -  dual therapy including a prostacyclin.

                    -  or dual therapy including an endothelin receptor antagonist and a

               -  5-phosphodiesterase inhibitors, in patients with contra-indication of
                  prostacyclin, poor tolerance to this treatment, prostacyclin derivative treatment
                  failure or patient refusal.

               -  Valid status in the social security system

               -  Signed informed consent

        Exclusion Criteria:

          -  Patient eligible for pulmonary transplantation

          -  Pregnancy or breastfeeding

          -  Adults of the age of majority subject to guardianship court order or deprived of
             liberty

          -  Patient with history of radio frequency procedure

          -  Known heparin allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vanina OLIVERI, PM</last_name>
    <phone>0033 4 92 03 40 11</phone>
    <email>drc@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean Louis BONNET, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas CUISSET, PU-PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanina OLIVERI, Project Manager</last_name>
      <phone>0033 4 92 03 42 54</phone>
      <email>oliveri.v@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Emile FERRARI, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Priscille BOUVIER, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jérome RONCALI, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent TETU, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP</name>
      <address>
        <city>¨Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marc SAPOVAL, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier SANCHEZ, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

